X4 Pharmaceuticals (XFOR)
(Delayed Data from NSDQ)
$1.20 USD
+0.01 (0.42%)
Updated Apr 18, 2024 03:59 PM ET
After-Market: $1.20 0.00 (0.00%) 6:20 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
XFOR 1.20 +0.01(0.42%)
Will XFOR be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for XFOR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for XFOR
What Makes X4 Pharmaceuticals (XFOR) a New Buy Stock
All You Need to Know About X4 Pharmaceuticals (XFOR) Rating Upgrade to Buy
XFOR: What are Zacks experts saying now?
Zacks Private Portfolio Services
X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Misses Revenue Estimates
Other News for XFOR
X4 Pharmaceuticals: PDUFA Excitement Ahead
Commit To Buy X4 Pharmaceuticals At $1, Earn 48.2% Annualized Using Options
X4 Pharmaceuticals Updates Corporate Presentation Online
X4 Pharmaceuticals on the Brink: The Race Against Nasdaq Delisting and Investor Confidence
Buy Rating Affirmed on X4 Pharmaceuticals Amid Positive Mavorixafor Prospects